-- 周四上午晚些时候，欧洲股市在美国交易，美国存托凭证（ADR）走低，标普欧洲精选ADR指数下跌0.42%，至1823.55点。 欧洲大陆方面，生物制药公司Cellectis (CLLS)和互联网浏览器公司Opera (OPRA)领涨，分别上涨4.4%和3.7%。紧随其后的是石油炼制公司Equinor (EQNR)和软件公司SAP (SAP)，分别上涨3.6%和3.1%。 欧洲大陆方面，半导体公司Sequans Communications (SQNS)和生物技术公司Evaxion (EVAX)领跌，分别下跌3%和1.6%。紧随其后的是生物制药公司DBV Technologies (DBVT)和argenx (ARGX)，分别下跌1.3%和1.1%。 英国股市涨幅居前的股票包括制药公司Silence Therapeutics (SLN)和通讯公司WPP (WPP)，分别上涨4.3%和2.8%。紧随其后的是教育出版商培生集团(PSO)和石油天然气公司BP (BP)，分别上涨2.4%和2.1%。 英国和爱尔兰股市跌幅居前的股票包括邮轮运营商嘉年华(CUK)和生物制药公司Bicycle Therapeutics (BCYC)，分别下跌4.6%和2.8%。紧随其后的是生物制药公司NuCana (NCNA)和制药公司葛兰素史克(GSK)，分别下跌1.7%和0.9%。
Related Articles
Asia
Update: Origin Energy Reports Lower March Quarter Production; Shares Fall 3%
(Updates to add stock movement in the headline and last paragraph)Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.The company reported commodity revenue of AU$1.86 billion for the quarter, down from AU$ 2.31 billion a year ago, per the filing.Origin Energy also said its electricity sales volume increased 4% from a year earlier amid "strong growth" in business volumes driven largely by the data-center sector.The company's shares fell 3% in recent Monday trade.
$ASX:ORG
Asia
Alterity Therapeutics Secures US FDA Support for ATH434 Phase Three Program
Alterity Therapeutics (ASX:ATH) said it received positive feedback from a second type C meeting with the US Food and Drug Administration (FDA) on its planned phase three program for drug candidate ATH434, aimed at treating multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.MSA is a progressive neurodegenerative disorder affecting autonomic and motor function with no approved disease-modifying therapies.The US FDA provided supportive written feedback on the program's chemistry, manufacturing, and controls, complementing earlier guidance from a separate type C meeting on clinical pharmacology and non-clinical development, the filing added.
$ASX:ATH
Asia
Xinyuan Property Management's CFO Resigns
Xinyuan Property Management Service's (HKG:1895) chief financial officer, Wang Yong, has resigned, effective April 26, according to a Monday Hong Kong bourse filing.Wang stepped down to devote more time to personal commitments, the company said.The company said the resignation will not affect its normal operations, with Wang's duties to be reallocated internally on an interim basis.Xinyuan Property Management added that it is seeking a suitable replacement for the chief financial officer role.
$HKG:1895